Jean-Charles Soria
Jean-Charles Soria
Gustave Roussy and University Paris Saclay
Adresse e-mail validée de gustaveroussy.fr
Titre
Citée par
Citée par
Année
Pembrolizumab for the treatment of non–small-cell lung cancer
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
44822015
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ...
Nature 515 (7528), 563-567, 2014
37972014
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...
New England journal of medicine 378 (2), 113-125, 2018
21712018
DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy
KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ...
New England Journal of Medicine 355 (10), 983-991, 2006
21542006
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
21422018
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ...
European journal of cancer 54, 139-148, 2016
12902016
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
10752012
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
7732017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
7202017
Rociletinib in EGFR-mutated non–small-cell lung cancer
LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ...
New England Journal of Medicine 372 (18), 1700-1709, 2015
7112015
Management of non-small-cell lung cancer: recent developments
M Reck, DF Heigener, T Mok, JC Soria, KF Rabe
The Lancet 382 (9893), 709-719, 2013
7022013
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ...
Annals of Oncology 27 (4), 559-574, 2016
6552016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ...
Nature reviews Clinical oncology 13 (8), 473-486, 2016
6432016
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert, JC Soria, A Spatz, A Le Cesne, D Malka, P Pautier, J Wechsler, ...
The lancet oncology 6 (7), 491-500, 2005
6322005
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ...
The Lancet 387 (10026), 1415-1426, 2016
6022016
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ...
New England Journal of Medicine 382 (1), 41-50, 2020
5782020
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation
JC Soria, HY Lee, JI Lee, L Wang, JP Issa, BL Kemp, DD Liu, JM Kurie, ...
Clinical Cancer Research 8 (5), 1178-1184, 2002
4792002
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous …
F Barlesi, A Scherpereel, A Rittmeyer, A Pazzola, NF Tur, JH Kim, MJ Ahn, ...
Journal of Clinical Oncology 31 (24), 3004-U109, 2013
474*2013
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non–small-cell lung cancer: a meta-analysis
C Delbaldo, S Michiels, N Syz, JC Soria, T Le Chevalier, JP Pignon
Jama 292 (4), 470-484, 2004
4622004
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non–small-cell lung cancer
LV Sequist, B Besse, TJ Lynch, VA Miller, KK Wong, B Gitlitz, K Eaton, ...
Journal of clinical oncology 28 (18), 3076-3083, 2010
4352010
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20